Literature DB >> 31144245

Atrial Fibrillation in Heart Failure-Diagnostic, Therapeutic, and Prognostic Relevance.

Clara Stegmann1, Gerhard Hindricks2.   

Abstract

PURPOSE OF REVIEW: Atrial fibrillation (AF) and heart failure (HF) commonly coexist and are associated with an increased risk of hospitalization, morbidity, and mortality. Both conditions develop into epidemics due to the ageing of the population and lead to poorer prognosis for the individual patients. Therapeutic strategies include treatment with oral anticoagulation, and rate and rhythm control concepts to prevent stroke and improve the cardiovascular outcome. RECENT
FINDINGS: Especially in HF patients, data suggest that catheter ablation of AF is superior to medical treatment. In patients with both AF and HF undergoing catheter ablation, significant increases in left ventricular ejection fraction and quality of life and decreases in related symptoms and major adverse cardiac events are reported. In addition, catheter ablation has been shown to reduce mortality and HF hospitalization in the medium term. For patients with AF and HF, an effective individualized therapeutic strategy to minimize potential complications and improve clinical outcomes is needed. Catheter ablation of AF seems to provide advantages in HF patients with AF. However, results of further long-term studies are awaited.

Entities:  

Keywords:  Atrial fibrillation; Catheter ablation; Heart failure; Rate control; Rhythm control

Mesh:

Substances:

Year:  2019        PMID: 31144245     DOI: 10.1007/s11897-019-00430-5

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN: 1546-9530


  65 in total

Review 1.  Clinical epidemiology of heart failure.

Authors:  Arend Mosterd; Arno W Hoes
Journal:  Heart       Date:  2007-09       Impact factor: 5.994

2.  Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure.

Authors:  D Li; K Shinagawa; L Pang; T K Leung; S Cardin; Z Wang; S Nattel
Journal:  Circulation       Date:  2001-11-20       Impact factor: 29.690

3.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.

Authors:  Paulus Kirchhof; Stefano Benussi; Dipak Kotecha; Anders Ahlsson; Dan Atar; Barbara Casadei; Manuel Castella; Hans-Christoph Diener; Hein Heidbuchel; Jeroen Hendriks; Gerhard Hindricks; Antonis S Manolis; Jonas Oldgren; Bogdan Alexandru Popescu; Ulrich Schotten; Bart Van Putte; Panagiotis Vardas; Stefan Agewall; John Camm; Gonzalo Baron Esquivias; Werner Budts; Scipione Carerj; Filip Casselman; Antonio Coca; Raffaele De Caterina; Spiridon Deftereos; Dobromir Dobrev; José M Ferro; Gerasimos Filippatos; Donna Fitzsimons; Bulent Gorenek; Maxine Guenoun; Stefan H Hohnloser; Philippe Kolh; Gregory Y H Lip; Athanasios Manolis; John McMurray; Piotr Ponikowski; Raphael Rosenhek; Frank Ruschitzka; Irina Savelieva; Sanjay Sharma; Piotr Suwalski; Juan Luis Tamargo; Clare J Taylor; Isabelle C Van Gelder; Adriaan A Voors; Stephan Windecker; Jose Luis Zamorano; Katja Zeppenfeld
Journal:  Europace       Date:  2016-08-27       Impact factor: 5.214

Review 4.  Role of AV nodal ablation in cardiac resynchronization in patients with coexistent atrial fibrillation and heart failure a systematic review.

Authors:  Anand N Ganesan; Anthony G Brooks; Kurt C Roberts-Thomson; Dennis H Lau; Jonathan M Kalman; Prashanthan Sanders
Journal:  J Am Coll Cardiol       Date:  2012-02-21       Impact factor: 24.094

5.  Functional status in rate- versus rhythm-control strategies for atrial fibrillation: results of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Functional Status Substudy.

Authors:  Mina K Chung; Lynn Shemanski; David G Sherman; H Leon Greene; David B Hogan; Joyce C Kellen; Soo G Kim; Lisa Warsinger Martin; Yves Rosenberg; D George Wyse
Journal:  J Am Coll Cardiol       Date:  2005-10-21       Impact factor: 24.094

Review 6.  Atrial fibrillation in heart failure with preserved ejection fraction: Insights into mechanisms and therapeutics.

Authors:  Ravi B Patel; Muthiah Vaduganathan; Sanjiv J Shah; Javed Butler
Journal:  Pharmacol Ther       Date:  2016-10-20       Impact factor: 12.310

7.  Increased mortality after dronedarone therapy for severe heart failure.

Authors:  Lars Køber; Christian Torp-Pedersen; John J V McMurray; Ole Gøtzsche; Samuel Lévy; Harry Crijns; Jan Amlie; Jan Carlsen
Journal:  N Engl J Med       Date:  2008-06-19       Impact factor: 91.245

Review 8.  Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials.

Authors:  Qinmei Xiong; Yee Cheng Lau; Keitaro Senoo; Deirdre A Lane; Kui Hong; Gregory Y H Lip
Journal:  Eur J Heart Fail       Date:  2015-09-03       Impact factor: 15.534

9.  A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure.

Authors:  David G Jones; Shouvik K Haldar; Wajid Hussain; Rakesh Sharma; Darrel P Francis; Shelley L Rahman-Haley; Theresa A McDonagh; S Richard Underwood; Vias Markides; Tom Wong
Journal:  J Am Coll Cardiol       Date:  2013-03-07       Impact factor: 24.094

10.  Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study.

Authors:  Sumeet S Chugh; Rasmus Havmoeller; Kumar Narayanan; David Singh; Michiel Rienstra; Emelia J Benjamin; Richard F Gillum; Young-Hoon Kim; John H McAnulty; Zhi-Jie Zheng; Mohammad H Forouzanfar; Mohsen Naghavi; George A Mensah; Majid Ezzati; Christopher J L Murray
Journal:  Circulation       Date:  2013-12-17       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.